Osiflu 75 Capsule contains Oseltamivir Phosphate 75 mg, an antiviral medication primarily indicated for the treatment and prevention of influenza A and B virus infections. Oseltamivir is a neuraminidase inhibitor that impedes the release of new viral particles from infected cells, thereby limiting the spread of the virus within the respiratory tract. It is most effective when administered within 48 hours of the onset of influenza symptoms, such as fever, cough, sore throat, body aches, and fatigue. Osiflu 75 Capsule is prescribed to reduce the duration and severity of influenza symptoms and to prevent influenza in individuals exposed to the virus. The medication is suitable for adults and children over one year of age, with dosage adjustments based on age and renal function. Common side effects may include nausea, vomiting, headache, and abdominal discomfort, which are generally mild and transient. Patients with known hypersensitivity to Oseltamivir or any component of the formulation should avoid use. Osiflu 75 Capsule should be used under medical supervision, particularly in patients with pre-existing medical conditions or those taking concomitant medications. It is not a substitute for influenza vaccination but serves as an adjunct in managing influenza infections.